Michigan’s Bio-Industry Strategic Roadmap to be Updated

May 29, 2024

Charting the Future of Michigan’s Biosciences Industry

MichBio, the association for Michigan’s biosciences industry, announced during the 2024 Mackinac Policy Conference that it is launching a statewide effort to update the Michigan Bio-Industry Roadmap for Success. The Roadmap is a strategic plan released in early 2016 for growing Michigan’s biosciences industry into a global leader. 



“Michigan’s bio-industry is at a critical point given the rapidly changing dynamics in the worldwide marketplace and healthcare delivery landscape”, remarked Stephen Rapundalo, MichBio President and CEO. “While our statewide bio-industry cluster has witnessed good growth in recent years, other U.S. regions, many with lesser industry footprints and research innovation strength than Michigan, have been far more aggressive and successful in developing their life sciences hubs. It is imperative to develop a shared and executable vision for supporting Michigan’s bio-industry that can retain both our STEM and trades talent in high-wage jobs.” 

The updated Roadmap is an operational “game plan” to enable growth over the next five years. The planning effort will identify key strategies to expand the different sectors that make up the bio-industry including pharmaceuticals, medical products and technologies, research and testing, agricultural/industrial biotechnology, health technologies, and bioscience distribution. In addition, the initiative will define priorities for spurring innovation, improving the business climate and capital access, and developing talent for all skill levels. 


“It is important to note that the biosciences are the one industry where Michigan has all the needed ingredients to realize economic success. This begins with our world-class research institutions that deliver discoveries and serve as the substrate for commercialization, and ultimately, the development of life-changing treatments for patients,” said Britany Affolter-Caine, University Research Corridor (URC) Executive Director. “A roadmap that integrates stakeholders from across the state is critical to sustain, much less grow, an R&D and biomanufacturing ecosystem that is the envy of others.” 


The road mapping effort will be overseen by an executive steering committee comprised of bio-industry experts from around Michigan: 


Outreach to bio-industry stakeholders is planned in the form of a statewide listening tour, interviews, focus groups, and surveys. Data gathered will validate key strategic themes and areas, identify new unmet needs and growth opportunities, and help develop policy proposals for legislative action. Existing MichBio workgroups (Committees) will support the steering group in developing the Roadmap. The final report will include recommendations around goals, performance measures and responsible parties for delivering outcomes. 

“Accelerating the success of Michigan’s life science industry requires a mission-driven mindset to nurture growth,” says Rapundalo. “Our core challenge – and great opportunity – is to bring synergies together around our assets and capabilities, direct them in a manner that empowers all stakeholders, and allows the industry to flourish. The Roadmap seeks to be the beacon for executing on that mission. The time for action is now.” 


———————— 


MichBio is the only statewide trade association committed to driving growth in Michigan’s biosciences industry and its many sectors, including agricultural/industrial biotech, medical devices, pharmaceuticals, academic/clinical research, testing and research services, healthcare and information technologies, and bioscience products distribution. MichBio members include bioscience companies, research institutions, manufacturing suppliers and service providers, and related organizations. MichBio is here to support Michigan’s bioscience researchers, innovators, and producers, as well as those in the broader ecosystem that serve to sustain them. Through advocacy, programming, connecting, and business resources we help the state’s biosciences community thrive. For more information, visit www.michbio.org or follow us on LinkedIn and X. 

RECENT ARTICLES

April 24, 2025
Prenuptial Patenting: Responsible Engagement with Engineering Firms
April 24, 2025
PharmOptima, a Poratge, Michigan-based preclinical contract research organization (CRO) is advancing drug discovery through its comprehensive suite of services. Specializing in in-vivo ADME/PK, ocular research, as well as regulated large and small molecule bioanalytical and ligand binding services, PharmOptima supports clients in optimizing drug development programs efficiently and effectively. With a staff averaging 11 years of industry experience and multiple individuals with advanced degrees, PharmOptima also boasts one of the most capable and engaging teams in the industry. The company collaborates with board-certified veterinary ophthalmologist Dr. Ryan Boyd, further enhancing its ocular research capabilities. PharmOptima's team of experts is dedicated to providing high-quality services to the pharmaceutical biotechnology industries. Looking ahead, PharmOptima scientists will be presenting posters at the 2025 The Association for Research in Vision and Ophthalmology (ARVO) conference, showcasing their latest research and innovations in ocular drug development. For more information visit www.pharmoptima.com .
April 24, 2025
Two bills, HB 4332 and HB 4333 were recently re-introduced that would prohibit pathogen gain-of-function (GoF) research. Given that the House is now Republican-led raises concerns for MichBio and others that the legislation might gain traction due to misinformation over biosafety and pandemic origins. MichBio opposes such broad legislative bans as they risk undermining critical scientific progress, public health preparedness, and economic innovation. GoF research has been instrumental in developing life-saving therapies and vaccines. For instance, viral vector-based gene therapies, such as Sarepta's Elevidys for Duchenne muscular dystrophy, and oncolytic virotherapies like Amgen's Imlygic for melanoma, rely on genetically modified viruses to deliver therapeutic genes or selectively destroy cancer cells. These advancements stem from GoF methodologies that enhance viral capabilities for therapeutic purposes. Moreover, GoF research has played a pivotal role in vaccine development. Examples like the AstraZeneca and Janssen COVID-19 vaccines and Merck's ERVEBO vaccine against Ebola employs a genetically modified virus to confer protection, underscore the public health benefits derived from GoF studies. ​ Contrary to concerns that GoF research operates without sufficient oversight, multiple layers of regulation are in place. Since 2017, the U.S. Department of Health and Human Services has implemented a framework to evaluate and guide funding decisions for GoF research, particularly those involving potential pandemic pathogens. This framework includes stringent safety protocols, risk assessments, and ethical reviews. ​ MichBio is most concerned that any legislative bans that broadly define and prohibit GoF research risk stifling innovation across various scientific fields. Such bans could inadvertently encompass research in virology, microbiology, molecular biology, and synthetic biology—disciplines vital for developing new therapies, sustainable agricultural practices, and environmental remediation technologies. ​ In turn, state-level bans on GoF research could have detrimental effects on local economies and academic institutions. Such a ban could impede research critical to understanding and combating diseases, leading to a loss of federal and philanthropic funding. This could hamper the growth of the Michigan's biotech and biomedical sectors. ​  MichBio advocates for a balanced approach that reinforces existing oversight mechanisms and fosters transparent, responsible research practices essential to safeguard both public health and scientific progress.